Brefeldin A

For research use only. Not for use in humans.

Catalog No.S7046

18 publications

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Brefeldin A has been cited by 18 publications

3 Customer Reviews

  • Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

  • Immunofluorescence staining of LC3 protein expression of U2OS cells treated with DMSO (negative control), Rap (positive control, 500 nM), Tha (1 μM), Tun (2 μg/mL), BFA (10 μg/mL), and DTT (4 mM) for 8 h. Immunoblot of ER-phagy-related proteins of U2OS cells treated with four ER stress inducers.

    Nanoscale, 2018, 10(18):8796-8805. Brefeldin A purchased from Selleck.

  • CSFV proliferation in ST cells with or without BFA was observed by IFA at 24, 48 and 72 hpi.

    J Biosci, 2018, 42(1):43-56. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NUH1eZI4TnWwY4Tpc44hSXO|YYm= MmDoNkDPxE1? M4ixelEhcA>? MXXpcohq[mm2czD0bIUhVC2GT2DBJEgzOMLizszNLU1qdmS3Y3XkJJRz[W6|aXXueEBGWktzL{KgdIhwe3Cqb4L5cIF1cW:wwrC= NVu1emptOjZ|NkOxPVE>
C2C12 M1S2VGZ2dmO2aX;uJGF{e2G7 MlG3NeKh|rypL33s M3rQbVHDqGh? MVLhZo9tcXOqZYOgZ5l1d2urbnWgdoVt\WG|ZTDmdo9uKEN{Q{GyJI16d3S3YnXz M{PLVVI3OjlzMke5
MEFs WT MWXGeY5kfGmxbjDBd5NigQ>? NHiyRYQ2yqEQvF2= MkC4NlAhdWmw NYrhcXYz[2G3c3XzJJJme2mmZX70JIVvgnmvZYOgd5VkcCCjczDORWdVNUeIUDygeI8h\GmoZoXz[UBj[WOtIITvJJRp\SCHUh?= M2nCWVI3OTl4MEKz
MEFs VAMP7 KO MYHGeY5kfGmxbjDBd5NigQ>? M4XvUlXDqM7:TR?= MYeyNEBucW5? MVrjZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT Mkm4NlYyQTZyMkO=
SMCs NF3qOZZHfW6ldHnvckBCe3OjeR?= M{GyOlExyqEEtXevcYw> MonlNE0yOiCq NI\6fZJFVVOR M2nQ[ZNpd3e|IHGgeJJmdmRidH;3ZZJleyCjIHjp[4hmeiClb37j[Y51emG2aX;uJI9nKHSqZTDFVk9UWiCwZYT3c5JsKGmwIITo[UBx\XKrboXjcIVieiCjcnXhxsA> M1POUVI3OTd{MEiw
SMCs MYjGeY5kfGmxbjDBd5NigQ>? NYfWToNJOTEEoNM1[{9udA>? NE\HZ28xNTF{IHi= MWDEUXNQ M{G2[4NifXOnczDhJJRz[W6|aXXueEBE[TJtwrDy[Yxm[XOnIH\yc40hfGinIFXSM3NTyqB? M{LRPVI3OTd{MEiw
HEMC-1 M3LzXmZ2dmO2aX;uJGF{e2G7 NHe5OmgxNjIEoNM1[{9udA>? MYiyOOKhcA>? MYXjZZV{\XNiYTDobYdp\XJiaX7obYJqfG:{eTDl[oZm[3Rib36g[Zhw[3m2b4Ppd{B1cGGwIH7vZ49l[XqxbHW= M3XUd|I2QTd{N{W5
HUVEC NEf5XYlHfW6ldHnvckBCe3OjeR?= NWq1W21XOTEEoN88US=> MonFNeKhcA>? M1n3dmROW09? MkOwZYJwdGm|aHXzJIh6eG:6aXGtbY5lfWOnZDDy[Yxm[XOnIH;mJGFVWCCocn;tJIFxcWOjbDDhcoQh[mG|b3zheIVz[Wxic4Xy[oFk\XN? MnL2NlU6PTZ7OEi=
HUVEC NELHVZFHfW6ldHnvckBCe3OjeR?= M4LJeFExyqEQvF2= MlGyNeKhcA>? MX\EUXNQ M3TTRolv[3KnYYPld:KhfGinIH71cYJmeiCjbnSgbY51\W6|aYT5JI9nKG[udX;y[ZNk\W62IHHy[YF{KGW|cHXjbYFtdHliaX6gdIVzcW63Y3zlZZIhe3CjY3W= MnrZNlU6PTZ7OEi=
Caco-2 MkHsSpVv[3Srb36gRZN{[Xl? MWSyMlUh|ryP NIDMN4s{OCCvaX6= NH\CV2RifHSnboXheIV{KHSqZTDUS2Yu|rJzLX3l[IlifGWmIHnuZ5Jm[XOnIHnuJHNGWlRiZoXuZ5Rqd25? MmjqNlU6PTR7M{G=
NRK M{XFemZ2dmO2aX;uJGF{e2G7 MVuyNFDjiIWwZz;tcC=> NV\sTFg2POLChXi= NVf5UJJbTE2VTx?= MXzy[ZNkfWW|IH3peI91cWNicILv[5Jme3Orb36= M2Ty[|I2QTR6NUi2
HeLa NYLzUWRFTnWwY4Tpc44hSXO|YYm= NETicHMzODEkgJXu[{9udA>? NYXycmFROyCq NFTGZYdFVVOR NUnrfHRGcW6mdXPld{B1cGViYYL0bYZq[2mjbDDidoVicy23cDDv[kB1cGViR3;s[4kh[2:vcHzlfC=> NWPqdI9bOjV7NEi1PFY>
COS MmXVSpVv[3Srb36gRZN{[Xl? NYOwcJVtOSEQvHevcYw> MWezJIg> MYPjc41xdGW2ZXz5JIRqe3CncoPld{B1cGViQWCtNUB{cWewYX|CpC=> MlrmNlU6OTV7MEC=
DF1  M{\TUmZ2dmO2aX;uJGF{e2G7 NYr0W5RlOcLizszNxsA> MXS0PEBp MlXRSG1UVw>? MmTJ[Il{eGW{c3XzxsB1cGViZYjv[4Vvd3W|IFPTS4FtVkGlVEKgdJJwfGWrbh?= MWGyOVgxPzB3NB?=
nHDFs  M4HoSGZ2dmO2aX;uJGF{e2G7 MUixxsDPxE4EoB?= M1XEdlLDqGh? NE\3[4RxemW4ZX70d{B1cGViYYPz[Y1jdHlib3[gZ5l1d3OxbHnjJINw[XRicILveIVqdnNib370c{BId2ypaTDt[Y1jemGwZYO= MojrNlU4PzJ4MU[=
FRT  NX7UdIJQTnWwY4Tpc44hSXO|YYm= M1ntUFUh|rypL33s M2P2XFLDqGh? NIGyb4VjdG:la4OgeJJi\m[rY3vpcochfGi{b4XnbEB1cGViR3;s[4kh[2:vcHzlfEBjgSCrbnjpZol1cW6pIFXSMZRwNUexbHfpJJRz[W6|cH;yeC=> M4i3bFI2PzZ5MUG1
FRT  NFzsWXlHfW6ldHnvckBCe3OjeR?= NUPjR3k{PSEQvHevcYw> MmPJNuKhcA>? MmX0dJJmfmWwdIOgeIhmKGmwY4LlZZNmKGmwIHPs[YF3\WRizsGgd5VjfW6rdIOge4hmdiCdTnGrYYnDqHejczDy[YR2[2Wm M4nLeFI2PzZ5MUG1
HepG2  NVjQfYRFTnWwY4Tpc44hSXO|YYm= NYrI[YlTOeLCidM1UeKh M4PnWVI1KGh? Mn\VSG1UVw>? NXTQ[YhX\GWlcnXhd4V{KHSqZTDs[ZZmdCCxZjDQXHIhdVKQQR?= NFzLOmYzPTZzNkW5Oy=>
SMCs MVXGeY5kfGmxbjDBd5NigQ>? MVqx{txoN22O NYK4bIdOOyCq MWfhZ4N2dXWuYYTld{BEVlC\MjDwdo91\WmwIHnuJJRp\SCHUjDjc41x[XK2bXXueEBidmRibn:gcI9v\2W{IHPvMYxw[2GuaYrl[EB4cXSqIITo[UBId2ypaTDtZZJs\XMEoB?= MYKyOVU5QTR{NR?=
OB-6 NID4OWlCeG:ydH;zbZMhSXO|YYm= MnL6Nk44yqEQvF2= MYO0PEBp MkLLbY5lfWOnczDhdI9xfG:|aYO= NIC5UWQzPTV|MkS4NC=>
iPSC-CMs  MkHuSpVv[3Srb36gRZN{[Xl? M{HRSlUxOCCwZz;tcC=> NXLaZ|M3PDhiaB?= M4LkeYlv[3KnYYPld{B1cGViaX70[Y5{cXS7IH;mJJRp\SCqaXfo[ZIhdW:kaXzpeJkhVEGPUIOgZZQhfGinIHPvd5Qhd2ZidHjlJIxwf2W{IH3vZoltcXS7IIPw[YNq\XN? MUWyOVQ5QDZ4Nh?=
SP-Nluc M{\GemZ2dmO2aX;uJGF{e2G7 NXPJcJBuPSCvZz;tUC=> M4HuOlYhcA>? NUPTenR5TE2VT9Mg Mlr0Z4F2e2W|IHHuJIlv[3KnYYPlJIlvKHKncH;yeIVzKGGldHn2bZR6KGmwIITo[UBx[XKjc3n0[S=> MYOyOVM6Ojl7OB?=
PEXEL-Nluc M3jDXWZ2dmO2aX;uJGF{e2G7 MmjPOUBu\y:vTB?= NGLReow3KGh? MoLUSG1UV8Li MXjjZZV{\XNiYX6gbY5kemWjc3WgbY4hemWyb4L0[ZIh[WO2aY\peJkhcW5idHjlJJBiemG|aYTl M4LWdFI2Ozl{OUm4
H1299 M2mwS2Z2dmO2aX;uJGF{e2G7 Ml\1NVAh|rypL33s NXLsV|NlOjRiaB?= Mn7UbY5lfWOnczDheZRweGijZ4pCpC=> M1\KcVI2Ozh6OUew
MDA-MB-231 NUPBd4tuS2WubDDWbYFjcWyrdImgRZN{[Xl? M17oeFDjiJN3MDFOwIcwdUx? NELZNWI1QCCq MmXRSWM2OMLiPTCwMlAyPiEEtXevcWw> NFvtWWUzPTN3NkW2Oy=>
MDA-MB-231 MknTRZBweHSxc3nzJGF{e2G7 MmTkNE4yKM7:Zz;tUC=> M37VPFQhcA>? NU[3dJo2cW6mdXPld{BieG:ydH;zbZM> MV:yOVM2PjV4Nx?=
MDA-MB-231 NF7EPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUewMlAyNzBwMEWg{txoN22O NV;0Vpo4OjRiaB?= M3jKdolv[3KnYYPld{B1cGViZoLhZ5Rqd25ib3[gd5VjNUdzIHPlcIwh\GWkcnnz MUCyOVM2PjV4Nx?=
MDA-MB-231 NX6xemlrSXCxcITvd4l{KEG|c3H5 MmTTNE4xPeLCk{Gg{txoN22O M2HzO|I1KGh? NV:1e2hWcW6mdXPld{BRSVKSIDjwc4x6KEGGUD3ybYJwe2VicH;sfY1memG|ZT2xLUBkdGWjdnHn[S=> NX;QNWoyOjV|NU[1Olc>
MDA-MB-231 NYHqXIFVTnWwY4Tpc44hSXO|YYm= MmTYNQKBmzVyIN88[{9uVA>? NUTXXnBFOjRiaB?= MX7pcohq[mm2czD0bIUh\m:{bXH0bY9vKG:oIEPEJIFv\CB{RDDjc4xwdmmncx?= M3HCS|I2OzV4NU[3
A172 M3zNfWZ2dmO2aX;uJGF{e2G7 MkXjNVDDqM7:Zz;tcC=> MnnkOOKhcA>? NHP5SoJFVVORwrC= MkPadoV{fWy2czDpckB1cGVicnX0do9oemGmZTD0doFve3CxcoSgc4Yh\my3b4Lld4NmdnRiZ4LhcpVt\XN? NF;oV3AzPTJ|OUWwOy=>
KMS-6 MlXYSpVv[3Srb36gRZN{[Xl? MVOxxsDPxE4EoB?= NGnwcVYzPCCq MVXlfIhq[mm2czDoZYxnKHSqZTDz[YNz\XSrb36gc4Yh\2GuYX7pck1NUSCjczDkbYQhfGinIHPvcpRzd2x? MYiyOVIzQTF{Nh?=
MEC MVHGeY5kfGmxbjDBd5NigQ>? NHK5NI4yKM7:TR?= MnXrNU42KGh? M3fMNINifXOnczDhJIRz[W2jdHnjJIRm[3KnYYPlJIlvKHSqZTDzeZJn[WOnIG\FS2ZTOg>? M2rXZVI2OjJ6OEG1
HEK293/hERG MnzrSpVv[3Srb36gRZN{[Xl? MlHCNVDDqM7:TR?= M1T3VFHDqGh? NGG2Tnlz\XO3bITzJIlvKGFidHnt[U1l\XCnbnTlcpQhemWmdXP0bY9vKG2jdIXy[UBpTVKJIIDyc5RmcW8EoB?= NXv5TWg2OjV{MUi0Olk>
RBE4 NInsRXZCeG:ydH;zbZMhSXO|YYm= NWSyXHhROsLizszN NWfjdmZiO+LCk{K0xsBp NEnWT2lqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHTldIVv\GWwdHz5 MnXuNlUyOjhyMkW=
RBE4 MYDGeY5kfGmxbjDBd5NigQ>? MWiyxsDPxE1? MojXN-KBmzJ2wrDo MVHpcoNz\WG|ZYOgeIhmKFiEUEGgdJJwfGWrbjDs[ZZmdHNiYX\0[ZIhOyCjbnSgOuKhcCCxZjD0doVifG2nboS= M1PVeVI2OTJ6MEK1
RBE4 M{XXVGZ2dmO2aX;uJGF{e2G7 M2XnO|LDqM7:TR?= MmG3N-KBmzJ2wrDo NILrVIdqdmO{ZXHz[ZMh[WO2aY\lJINie3Cjc3WtNVIhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZLDqA>? NUjseXRJOjVzMkiwNlU>
RBE4 NYrJU2VTTnWwY4Tpc44hSXO|YYm= NH7oOXQzyqEQvF2= MWOz5qCUOjUEoHi= M3n4Uolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIGLPV{B1cW2nLXTldIVv\GWwdHz5 MVuyOVEzQDB{NR?=
RBE4 MlT0SpVv[3Srb36gRZN{[Xl? M1nKRVLDqM7:TR?= MkPJN-KBmzJ2wrDo MV3pcoR2[2W|IHGg[IVt[XmnZDDk[ZBt\XSrb36gc4YhfGinIFXSJGNiOiwEoHPvcpRmdnRiYYSgOuKhcCCxZjDpcoN2[mG2aX;uJJNq\26rZnnjZY51dHl? M{fNWVI2OTJ6MEK1
RBE4 NYDRfFk4TnWwY4Tpc44hSXO|YYm= M3LyW|LDqM7:TR?= MoLKN-KBmzJ2wrDo MXHpcoR2[2W|IHHuJI93\XKub3HkJI9nKEOjMjxCpIlvKHSqZTDtbZRw[2ixbnTybYEhcW5idHjlJIZqenO2IEdCpIghd2ZiaX7jeYJifGmxbjCodQKBkT{kgJmwMlAxOSliYoX0JGNiOiwEoHzleoVteyCrbjD0bIl{KG:{Z3Hu[Yxt\SCmZXPy[YF{\WRiYX\0[ZIhOTMEoHigc4YhcW6ldXLheIlwdg>? M1HFWFI2OTJ6MEK1
Huh-7  M4XpbWZ2dmO2aX;uJGF{e2G7 M{fmVFHPxGdxbVy= MmrJN-KBmzJ2wrDo M{XOVYlv[3KnYYPld{B1cGVibHX2[Ywhd2ZiQWDFNUBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MnzRNlUxOjZzN{S=
HepG2  MXfGeY5kfGmxbjDBd5NigQ>? Mnf4Ne69\y:vTB?= NV\wWWluO+LCk{K0xsBp NFv4cVNqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIFHQSVEhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NVmxUIFVOjVyMk[xO|Q>
H838-LKB1 MXTGeY5kfGmxbjDBd5NigQ>? MWKzNOKhdmdxbXy= M4PaZlEzNzF6IHi= MoHNbY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCEaWFCpC=> M2DEOVI2ODFzMEiy
H838-KDLKB1  NGK5PZNHfW6ldHnvckBCe3OjeR?= NXv3VIFxOzEEoH7nM41t NFezdJQyOi9zODDo NVHoV|hOcW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? NF7GOlEzPTBzMUC4Ni=>
H838-KDLKB1  NYqwdHJCTnWwY4Tpc44hSXO|YYm= NETSOYs{OMLibnevcYw> NILtRlMyOi9zODDo M3WwVolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIDoc5NxcG:{eXzheIVlKGWLRkNOtUApeGixc4Doc{1mUUZ{zsGp NVjOXZJQOjVyMUGwPFI>
3T3-L1 MmnlSpVv[3Srb36gRZN{[Xl? MVm1JO69\y:vbB?= M4XBSlMxKG2rbh?= MkPJcYlucWO|IITo[UBm\m[nY4TzJI9nKGmwc4XsbY4h[W6mIHPheZNmeyC{b3L1d5QheGixc4Doc5J6dGG2aX;uJI9nKEGtdDCoV4VzKDR5MzmgZY5lKHCqb4PwbI9zgWyjdHnvckBw\iCDU{G2NEApXGi{IE[0NkBidmRiU3XyJFU5QCl? NXrmS3dCOjR6NEO4Nlc>
3T3-L1 MmfxSpVv[3Srb36gRZN{[Xl? NXHPNWQ2PSEQvHevcYw> MXKzNEBucW5? M{jweJJm[2GyaYT1cIF1\XNiaX7zeYxqdiCjY4Tpc44hf2m2aDDy[ZNx\WO2IITvJJJm\3WuYYTpcochSWu2IHHjeIl3cXS7IHHu[EBCWzF4MDDwbI9{eGixconsZZRqd25? NF3I[24zPDh2M{iyOy=>
3T3-L1 NXKxZZNITnWwY4Tpc44hSXO|YYm= MkDEOUDPxGdxbXy= Mm\GN|AhdWmw MUHjZZV{\XNicnX2[ZJ{cWKuZTDy[YRqe3S{aXL1eIlwdiCxZjDHUHVVPA>? MlvUNlQ5PDN6Mke=
3T3-L1 NYfrZlkxTnWwY4Tpc44hSXO|YYm= M3X0SVUh|rypL33s Mn\nNeKhcA>? MlfkZ4F2e2W|IILl[Il{fHKrYoX0bY9vKG:oIFfMWXQ1KGK3dDDuc5QhcW6lcnXhd4UhcW5iZ3z1Z49{\SC3cIThb4U> M373c|I1QDR|OEK3
3T3-L1 M13LNWZ2dmO2aX;uJGF{e2G7 MU[1JO69\y:vbB?= MlzKNeKhcA>? NF3IVo9k[XW|ZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJJRp\SCIb4jPNUB1emGwc3PybZB1cW:wIH\hZ5Rweg>? MV6yOFg1Ozh{Nx?=
HeLa  M2D3UGZ2dmO2aX;uJGF{e2G7 NVnOOnBbPSEQvHevcYw> NFj6cYs{KGh? NHv1dllk[XW|ZYOgcpVkdGWjcjDlfINtfXOrb36gc4YhfGinIF\vfG8yKHS{YX7zZ5JqeHSrb36g[oFkfG:{IHHu[EBl\WO{ZXHz[ZMhfHKjboPjdolxfGmxbjDv[kBHd3iRMT3y[Yd2dGG2ZXSg[4Vv\XN? M2LlflI1QDR|OEK3
HEK293 MmLXSpVv[3Srb36gRZN{[Xl? MoPsOeKh|rypL33s NHWyd2gyOsLiaB?= MonEZYJwdGm|aHXzJGNOSS2rbnT1Z4VlKEOURVzENkB{\WO{ZYTpc44> M3nZb|I1Pjh5NEOx
COS-1 MYjGeY5kfGmxbjDBd5NigQ>? NHzE[Zo2KML3Zz;tcC=> MnO5NlQhcMLi MoK3doV{fHKrY4TzJIxw[2GuaYrheIlwdiCxZjDORkBqdiC2aHWgdIVzcW63Y3zlZZIhemWpaX;uxsA> NY[yXoUxOjR4N{G3OVE>
PRP MVrGeY5kfGmxbjDBd5NigQ>? Ml\QNVAh|ryP M2DIeIFjem:pYYTld{BUTEZvMd8xMY1m\GmjdHXkJGNZS1J5IHX4eIVzdmGuaYrheIlwdsLi NW\Dfm9lOjR4Nki3OVA>
RAW264.7 NHrCdFVCeG:ydH;zbZMhSXO|YYm= M1rmT|Qh|ryP NVLsS2M4PDhiaB?= Mn7BZZR1\W63YYTld{B1cGViaX7obYJqfGmxbjDv[kBwgC2ORFytbY5lfWOnZDDhdI9xfG:|aYOgZY5lKHSqZTDmZYNqdGm2YYTpc44hd2ZiY3jvcIV{fGW{b3yg[YZndHW6IHL5JGFkNWiHLUG4RU1PUDJ? MUSyOFY{QTB|Mh?=
MDMs MkTRRZBweHSxc3nzJGF{e2G7 NEKw[GgyOOLCid88[{9udA>? NUfBUXhQOTJxMUWgbC=> NWTyXFN1cW6mdXPld{BieG:ydH;zbZM> MVqyOFU2PjZ7NR?=
PMHs  M{H1[GZ2dmO2aX;uJGF{e2G7 Ml3wNVDjiJN{MPMAje69\y:vbB?= NEW4VGEzPOLCiXi= NV6yOnNUTE2VTx?= M2PZXolv\HWlZXSgSXIhe3S{ZYPz MmT1NlQ1ODd{NEK=
PMHs  M1HYU2Fxd3C2b4Ppd{BCe3OjeR?= NICwZZcyOOLCk{Kw5qCK|rypL33s NUfYWI5vOjUkgJno NInDZXRFVVOR MoK1bY5kemWjc3XzJINmdGxiZHXheIg> MmHzNlQ1ODd{NEK=
HEK293/tau MoXkSpVv[3Srb36gRZN{[Xl? NXm4WFlDPSEQvF2= MmDUNU8zNzRiaB?= NFHDdY9qdmS3Y3XzJGdwdGerIH\yZYdu\W62YYTpc47DqA>? NX\RWoI4OjR|NkiwPFk>
HEK293/tau MWPGeY5kfGmxbjDBd5NigQ>? NGHVV442KM7:TR?= NYn1RZdLOyCq MVTpcoR2[2W|IITheUBpgXCncoDoc5NxcG:{eXzheIlwdg>? NU\mSJZ6OjR|NkiwPFk>
ADF NUniWYFqTnWwY4Tpc44hSXO|YYm= NXLxZollOTBizszN M4fUT|E3KGh? NWDOcnJmcW6qaXLpeJMhfGinIGruR4wzNWmwZIXj[YQhfHKjboPsc4NifGmxbjDv[kBEWlR? M3;sT|I1OjJ6MkOy
U373  NF7kc3lHfW6ldHnvckBCe3OjeR?= MVuxNEDPxE1? M3fkeVE3KGh? NHrQfWhqdmirYnn0d{B1cGViWn7DcFIucW6mdXPl[EB1emGwc3zvZ4F1cW:wIH;mJGNTXA>? MlfMNlQzOjh{M{K=
RKO-HIPK2i M4PiUGZ2dmO2aX;uJGF{e2G7 MmDsNVAh|ryP MlLRNVYhcA>? MmD4bY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> M4\JS|I1OjJ6MkOy
ADF  M4XjN2Z2dmO2aX;uJGF{e2G7 NX3FO5VCOTBizszNxsA> MnXLOkBp MXHpcZBicXK|IITo[UBFSyCjY4TpeoF1cW:w M3[xZVI1OjJ6MkOy
Huh7 NVPLNZJMTnWwY4Tpc44hSXO|YYm= NXzLUIk5PSEQvHevcYw> NX;Ye2l3PCCq NF;wNZli[m:uaYPo[ZMhfGinIIPlZ5JmfGmxbjDv[kAhcW62cnHj[YxtfWyjcjDBdI9D MVmyOFExODF2MB?=
Huh7 M1rMU2Z2dmO2aX;uJGF{e2G7 MorSOUDPxGdxbXy= MlGzNUBp NXLYd3JK[2G3c3XzJIEhe2mpbnnmbYNidnRiaX7jdoVie2ViaX6gRZBwSi2lcnXzZ4VvfHN? MUWyOFExODF2MB?=
Huh7 NGS1SmRHfW6ldHnvckBCe3OjeR?= M1jqb|XjiJNzMNMgcocwdWx? NXzZXZZ3OTJiaB?= M1mwNIlv[3KnYYPld{BCeG:ELXPy[ZNk\W62czD3bZRpd3W2IHnubIljcXSrbnegd4VkemW2aX;u MV2yOFExODF2MB?=
BAECs NFrDRppHfW6ldHnvckBCe3OjeR?= MUi1JO69\y:vbB?= M2f5fVAuPCCq MYDpcoR2[2W|IITo[UBz[XCrZDDk[ZBpd3OyaH;yfYxifGmxbjDv[kBmVk:VIHH0JHNmejFzN{m= MWeyOFA5PTJ{NR?=
Macrophages NFnne2ZHfW6ldHnvckBCe3OjeR?= NYTjTI9OPzFiwsXN MlHoOkBp M1XxbYlvcGmkaYTzJIx2dmG|aX6gbY51\XKwYXzpfoF1cW:wwrC= MkPJNlQxOzl5NEC=
Colo 205 NEXIfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv5fWJMOC13IN88[{9uVA>? NELwUZg1QCCq MmSzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5ic4XzdIVve2mxbjDjeYx1fXKnczD3bZRpKGGwIHXzeIlu[XSnZDDJR|UxKG:oII6xOUBv\y:vTB?= M2XISFI{QTd|OUm2
Colo 205 Mmf4SpVv[3Srb36gRZN{[Xl? MV6wMlAyOi1yLkCyOUDPxGdxbVy= MWGxOEBl NIrhNpRz\WS3Y3XzJJRp\SClbH;uc4dmdmmlaYT5JI9nKEOxbH:gNlA2KEOVQ4O= NX3PfHBoOjN7N{O5PVY>
Colo 205 MYLBdI9xfG:|aYOgRZN{[Xl? M3HobVAvOSEQvHevcWw> M3jRelAuOjRiaB?= M3X4bIlv\HWlZYOgZZBweHSxc3nzJI9nKEOxbH:gNlA2KGOnbHzzJIlvKHO3c4DlcpNqd25iY4XseJVz\XN? M1\tUFI{QTd|OUm2
Colo 205 MWjGeY5kfGmxbjDBd5NigQ>? MX6wMlAyPSEQvHevcWw> M4LSfVI1KGh? MWDpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFXSJJN1emW|cz3y[YxifGWmIHflcoV{ NXq2d5ZuOjN7N{O5PVY>
Colo 205 NXrUfIpJTnWwY4Tpc44hSXO|YYm= M2K0T|AvODF3IN88[{9uVA>? NGDV[3QzPCCq NVLtU4tFcW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJG1OWHN? MmPiNlM6PzN7OU[=
IBRS2 M4XvfGZ2dmO2aX;uJGF{e2G7 MVm1JO69\y:vbB?= M{nxeVAvPSCq NWf4ZlZHTE2VTx?= Mm\u[Il{enWydIOgeIhmKEWUR1nDJIFv\CCJb3znbeKh MVGyN|k3OzV|NB?=
IBRS2 MX;GeY5kfGmxbjDBd5NigQ>? M{nQV|Uh|rypL33s NVTpUlJyOC53IHi= NFfHfYJFVVOR NIraUJFmdmijbnPld{BHVUSYIHnu[oVkfGmxbh?= MUiyN|k3OzV|NB?=
HeLa MlT4SpVv[3Srb36gRZN{[Xl? NHO2U4UzKM7:TR?= MmO4NkBpyqB? NFLifohifHSnboXheIV{KHSqZTDUUmYucW6mdXPl[EB{\WO{ZYTpc44hd2ZiSVytNVU> M3HSRVI{QTVyOEmy
HFS  NEexe5pHfW6ldHnvckBCe3OjeR?= M13aT|AuOSEQvHevcYw> NIrvWmIzPCCq NIS0TohIVFSSIHX4dJJme3Orb36gdoVi[2inczDhJJBt[XSnYYWgZZQh[2:wY3XueJJifGmxboOgZZMhdG:5IHHzJFAvODFiwsXnM41t NFjNNWUzOzh7NE[zNy=>
HFS  NVm0eI1LTnWwY4Tpc44hSXO|YYm= NVnYVIdMOC5yMTFCuYcwdWx? MX2yOEBp NWXWe4NUcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGeueXPvd5BpcW6pb3zpdIllKHO7boToZZNmKGenbnXzJIF1KDZiaB?= MlLnNlM5QTR4M{O=
OVCAR-3 MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrTNgKBmzF3wrFOwG3DqA>? NFPaO|UzPMLiaB?= NUTuTIlRcW6mdXPld{BiKGyxc4Ogc4Yh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSuedMg MkmzNlM5OjZ7NkS=
OVCAR-3 MWjGeY5kfGmxbjDBd5NigQ>? NWfhXVNvOeLCk{G1xsDPxE4EoB?= NEfWPZczPMLiaB?= Mnz2bY5lfWOnczDueYNt\WG{IHThcYFo\Q>? MVqyN|gzPjl4NB?=
OVCAR-3 MWrBdI9xfG:|aYOgRZN{[Xl? NU[zZVV6OS1zMNMg{txO MUW0JIg> NXvxbZJkcW6mdXPld{B1cGViYXP0bZZifGmxbjDv[kBieG:ydH;zbZMuemWuYYTl[EBxem:2ZXnudy=> M4nYUFI{QDJ4OU[0
OVCAR-3 MUPBdI9xfG:|aYOgRZN{[Xl? NXTnflB{OTEEoN88US=> NYDr[IpZOjUEoHi= NWPGTZNIcW6mdXPld{Bi[3SrdnH0bY9vKG:oIHPhd5Bie2W| M4C1NlI{QDJ4OU[0
OVCAR-3 NWTHfIk1TnWwY4Tpc44hSXO|YYm= MYKx5qCUOTEEoN88US=> NXnUemRUOjUEoHi= M13UWYlv\HWlZYOg[Il{enWydHnvckBw\iC2aHWgcYl1d2Oqb37kdolidCC2cnHud41mdWK{YX7lJJBwfGWwdHnhcC=> MV:yN|gzPjl4NB?=
OVCAR-3 MoX5SpVv[3Srb36gRZN{[Xl? NE\WS5cy6oDVMUFCpO69VQ>? M1rkZlI1yqCq MVzpcoR2[2W|IH\vdo1ifGmxbjDv[kBz\WGldHn2[UBwgHmpZX6gd5Bm[2mncx?= MX6yN|gzPjl4NB?=
OVCAR-3 NIfVXHhHfW6ldHnvckBCe3OjeR?= MkjYNgKBmzFywrFOwG0> NX3aZ3kzOjUEoHi= MUXpcohq[mm2czDj[YxtKGGmaHXzbY9vKGGwZDDtbYdz[XSrb36= MoHmNlM5OjZ7NkS=
MKN45 NGXR[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm1eWNKSzVyPECuNFAyKM7:Zz;tcC=> M{T3W|I{Pzl|M{Sy
LOVO M1WyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLlTWM2OD1yLkGyJO69\y:vbB?= MYqyN|c6OzN2Mh?=
A549 M2nQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\SXWlEPTB;MD6wOEDPxGdxbXy= M3\NbVI{Pzl|M{Sy
MDA-MB-435 M2[3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7vTWM2ODxyLkCwNUDPxGdxbXy= NFj1O40zOzd7M{O0Ni=>
HepG2 NV3jT4VPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf3bItKUUN3MEywMlAxOSEQvHevcYw> NVz4SJk1OjN5OUOzOFI>
HL-60 M17FPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRDBwMECxJO69\y:vbB?= M3ry[|I{Pzl|M{Sy

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / GRP78 ; 

PubMed: 22859938     


(B) present the dose- and time- dependent effect of ER stress inducer brefeldin A on p53 expression. MCF-7 Cells were exposed to brefeldin A in 10% FBS–supplemented DMEM as time and dose indicated. The cell lysates were analyzed by western blotting with antibodies for p53, GRP78, and α-tubulin. The p53 protein expression level was quantified densitometrically. GRP78 served as an ER stress marker. 

22859938
Immunofluorescence
MTP / GBF1 ; 

PubMed: 26267806     


3T3-L1 cells, plated as above, were treated with brefeldin A (5 μg/ml, 3 hr), fixed and stained for MTP and GBF1. Brefeldin A treatment leads to redistribution of MTP from the juxtanuclear region, similar to what occurs with GBF1. Bars = 10 μm.

ErbB3 / Calnexin ; 

PubMed: 21576364     


293T cells transfected with ErbB3 were treated without (top) or with (bottom) BfA, and confocal immunofluorescence microscopy was used to examine the colocalization of ErbB3 with endogenous calnexin.

FMNL1 / GM130 ; 

PubMed: 21868368     


FMNL1 colocalizes with the cis-Golgi marker GM130 and is dispersed by treatment with brefeldin A (+BFA).

26267806 21576364 21868368
Growth inhibition assay
Cell viability; 

PubMed: 28462831     


Effects of brefeldin A on human prostate cancer cells. LNCaP and PC-3 cells were seeded in cell culture dishes and incubated for 24 h. The cells were then treated with different concentrations of brefeldin A for 72 h. The number of viable cells was determined by the trypan blue exclusion assay. Apoptosis was determined by propidium iodide staining and morphological assessment.

28462831

Protocol

Cell Research:

[5]

- Collapse
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A
Smiles CC1CCC/C=C/C2CC(O)CC2C(O)/C=C/C(=O)O1

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID